Business Context and Reporting Period
Allogene Therapeutics, Inc. filed this Form 8-K to report the results of its 2021 Annual Meeting of Stockholders held on June 10, 2021. The filing was signed and dated June 15, 2021. As of April 12, 2021, 141,485,913 shares of common stock were outstanding and entitled to vote.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating-performance metrics.
Material Changes Versus the Prior Comparable Period
The filing does not report financial or operational changes versus a prior comparable period. It reports only annual meeting voting results.
Meeting Results, Outlook, and Risks
- Election of directors: John DeYoung, Franz Humer, and Joshua Kazam were elected as Class III directors, each to serve until the 2024 Annual Meeting and until a successor is elected and qualified.
- Director voting: John DeYoung received 111,401,689 votes for, 8,576,418 withheld, and 8,764,205 broker non-votes. Franz Humer received 111,404,617 votes for, 8,573,490 withheld, and 8,764,205 broker non-votes. Joshua Kazam received 94,429,527 votes for, 25,548,580 withheld, and 8,764,205 broker non-votes.
- Executive compensation: Stockholders approved, on an advisory basis, the compensation of the named executive officers: 97,963,279 votes for, 22,027,420 against, 14,408 abstentions, and 8,764,205 broker non-votes.
- Independent auditor: Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021: 128,714,246 votes for, 17,530 against, and 10,536 abstentions.
- The filing provides no guidance, forecast, material contingency, or unusual financial item.
Important Facts to Verify
- Confirm the elected directors’ continued service and committee assignments through the 2024 annual meeting.
- Review the proxy statement for details of the named executive officer compensation approved on an advisory basis.
- Confirm Ernst & Young LLP’s appointment and any subsequent auditor-related developments for fiscal 2021.
- Because this 8-K contains no financial results, consult the company’s periodic reports for liquidity, cash runway, operating performance, debt, and clinical-development updates.